Having recently announced that it stands by its clinical trials after a former executive filed suit against the company for retaliatory termination after he raised concerns about the validity of studies conducted in Russia and Bulgaria, Mannkind has released new data from a Phase 3 bioequivalence study of its Afrezza inhaled insulin. The new data concern the equivalence of Afrezza delivered by the company’s original MedTone device and the new Gen2 delivery device. Read the company’s press release regarding the lawsuit. Read the company’s press release. announcing study results.
Mannkind announces positive Phase 3 results while facing clinical trial fraud accusations
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
